Anti-Müllerian hormone as an ovarian reserve marker in women with the most frequent muscular dystrophies

Medicine (Baltimore). 2020 Jun 5;99(23):e20523. doi: 10.1097/MD.0000000000020523.

Abstract

Some muscular dystrophies may have a negative impact on fertility. A decreased ovarian reserve is 1 of the factors assumed to be involved in fertility impairment. AMH (anti-Müllerian hormone) is currently considered the best measure of ovarian reserve.A total of 21 females with myotonic dystrophy type 1 (MD1), 25 females with myotonic dystrophy type 2 (MD2), 12 females with facioscapulohumeral muscular dystrophy (FSHD), 12 female carriers of Duchenne muscular dystrophy mutations (cDMD) and 86 age-matched healthy controls of reproductive age (range 18 - 44 years) were included in this case control study. An enzymatically amplified 2-site immunoassay was used to measure serum AMH level.The MD1 group shows a significant decrease of AMH values (median 0.7 ng/mL; range 0 - 4.9 ng/mL) compared with age-matched healthy controls (P < .01). AMH levels were similar between patients and controls in terms of females with MD2 (P = .98), FSHD (P = .55) and cDMD (P = .60).This study suggests decreased ovarian reserve in women with MD1, but not in MD2, FSHD and cDMD.

MeSH terms

  • Adult
  • Anti-Mullerian Hormone / blood*
  • Biomarkers / blood
  • Case-Control Studies
  • Female
  • Humans
  • Middle Aged
  • Muscular Dystrophies / blood*
  • Ovarian Reserve*
  • Prospective Studies
  • Young Adult

Substances

  • Biomarkers
  • Anti-Mullerian Hormone